ETTX News and Press, Entasis Therapeutics Holdings Inc. From 08/11/21

Entasis Therapeutics (NASDAQ:ETTX): Q2 GAAP EPS of -$0.29 beats by $0.03. As of June 30, 2021, cash and cash equivalents were $56.4 million, compared to $53.2 million as of December 31, 2020.  Press Release For further details see: Entasis Therapeutics EPS ...

-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021 SUL-DUR Launch Planning Progresses with Appointment of Anna Diaz Triola as Chie...

– Virtual Event to be Held Tuesday, August 24 at 10am Eastern Time – WALTHAM, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antib...

WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial...

WALTHAM, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced members of management will participate in the Wedbush Pac...

San Diego-based Kumquat Biosciences announced a $2 billion agreement with a Lilly subsidiary to discover small-molecule drugs that stimulate tumor-specific immune responses in cancer patients. Sirnaomics, a Maryland-Suzhou RNAi therapeutics company, filed to raise $300 million in a Ho...

Zai Lab (ZLAB) and Entasis Therapeutics (ETTX) announce the completion of enrollment in the late-stage trial of sulbactam-durlobactam (SUL-DUR) in patients with confirmed carbapenem-resistant Acinetobacter infections.The company said that it expects to post top-line data readout fro...

– First clinical trial to specifically study confirmed carbapenem-resistant Acinetobacter infections– – Phase 3 top-line data readout now anticipated in early 4Q 2021 – WALTHAM, Mass. and SHANGHAI, China and SAN FRANCISCO, July 27, 2021 (GLOBE N...

– Significant commercial strategy and product launch experience – – ATTACK Phase 3 top-line data readout remains on-track for 2H 2021 – WALTHAM, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-s...

Entasis Therapeutics Holdings (ETTX) presents preclinical data on ETX0462, a novel diazabicyclooctane with antimicrobial activity against multidrug-resistant ((MDR)) Gram-negative and biothreat pathogens, at the 2021 World Microbe Forum. Entasis scientists further demonstrated that the activi...